Therefore, we aimed to compare the clinical characteristics of ICI-treated and non-treated patients with EGFR-mutant lung cancers and to investigate the characteristics of those who benefited from immunotherapy in a prospective registry cohort of NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.